Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model

Amber Farooqui, Linxi Huang, Suwu Wu, Yingmu Cai, Min Su, Pengzhou Lin, Weihong Chen, Xibin Fang, Li Zhang, Yisu Liu, Tiansheng Zeng, Stephane G. Paquette, Adnan Khan, Alyson A. Kelvin, David J. Kelvina

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

6 Citas (Scopus)

Resumen

The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.

Idioma originalEnglish
Páginas (desde-hasta)7255-7264
Número de páginas10
PublicaciónAntimicrobial Agents and Chemotherapy
Volumen59
N.º12
DOI
EstadoPublished - dic. 1 2015
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
Copyright © 2015 Farooqui et al.

ASJC Scopus Subject Areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Huella

Profundice en los temas de investigación de 'Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model'. En conjunto forman una huella única.

Citar esto